These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36869646)

  • 1. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
    Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
    Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
    Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
    Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
    Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
    Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
    Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
    Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Marsavela G; Lee J; Calapre L; Wong SQ; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Abed A; Khattak MA; Meniawy TM; Dawson SJ; Sandhu S; Carlino MS; Menzies AM; Scolyer RA; Long GV; Amanuel B; Millward M; Ziman MR; Rizos H; Gray ES
    Clin Cancer Res; 2020 Nov; 26(22):5926-5933. PubMed ID: 33067256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE
    Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
    Lebow ES; Shaverdian N; Eichholz JE; Kratochvil LB; McCune M; Murciano-Goroff YR; Jee J; Eng J; Chaft JE; Kris MG; Kalashnikova E; Feeney J; Scalise CB; Sudhaman S; Palsuledesai CC; Malhotra M; Krainock M; Sethi H; Aleshin A; Liu MC; Shepherd AF; Wu AJ; Simone CB; Gelblum DY; Johnson KA; Rudin CM; Gomez DR; Razavi P; Reis-Filho JS; Isbell JM; Li BT; Rimner A
    Front Oncol; 2023; 13():1253629. PubMed ID: 37795442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
    Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
    Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Hou JY; Chapman JS; Kalashnikova E; Pierson W; Smith-McCune K; Pineda G; Vattakalam RM; Ross A; Mills M; Suarez CJ; Davis T; Edwards R; Boisen M; Sawyer S; Wu HT; Dashner S; Aushev VN; George GV; Malhotra M; Zimmermann B; Sethi H; ElNaggar AC; Aleshin A; Ford JM
    Gynecol Oncol; 2022 Nov; 167(2):334-341. PubMed ID: 36117009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.
    Chan WY; Lee JH; Stewart A; Diefenbach RJ; Gonzalez M; Menzies AM; Blank C; Scolyer RA; Long GV; Rizos H
    J Exp Clin Cancer Res; 2024 Aug; 43(1):238. PubMed ID: 39169411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.